RxDoctor Payments Data

Khin Aung, MD

Internal Medicine · Elmhurst, NYNPI 1679542864

Payments from drug & device makers

$400in general payments, 2019–2025

Across 18 payments — averaging $22.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$79
  • AbbVie$66
  • Gilead$58
  • Lilly USA, LLC$47
  • Renalytix AI, Inc.$46
  • Janssen Scientific Affairs, LLC$38
  • plus $65 from 3 others

What the payments were for

  • Food & beverage$400100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$400 in reported general payments places this provider in the 60th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$16,485
Medicare patients
49
Services billed
202

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin118$115,290
TrulicityDulaglutide49$73,438
JanuviaSitagliptin Phosphate69$70,504
EliquisApixaban91$67,106
OzempicSemaglutide47$50,274
EntrestoSacubitril/Valsartan66$50,161
FarxigaDapagliflozin Propanediol70$43,012
VascepaIcosapent Ethyl61$26,352
ProliaDenosumab15$25,829
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr46$24,502
XareltoRivaroxaban22$24,333
TradjentaLinagliptin34$22,897
Albuterol Sulfate HfaAlbuterol Sulfate162$6,368
Incruse ElliptaUmeclidinium Bromide16$5,326
Atorvastatin Calcium591$5,108

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity$47$73,43849 claims
Novo NordiskOzempic$17$50,27447 claims
GSKAnoro Ellipta, Incruse Ellipta$79$29,82962 claims
Johnson & JohnsonXarelto$25$24,33322 claims
AbbVieSynthroid$66$62414 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Elmhurst

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →